Though the different percutaneous valves have been designed and authorized for aortic stenosis with tricuspid valve, they have often been used to treat aortic regurgitation as an off-label indication.
The Jenavalve Trilogy valve has recently received the CE Mark for aortic regurgitation and aortic stenosis.
This study included 45 patients with severe AR.
Primary end point was technical success with <20 mmHg gradient and >1 AR reduction. Also major cardiac events were analyzed, defined as death, MI, stroke and need for cardiac surgery at discharge.
Mean age was 77, patients were mostly men, 10 were diabetic, 26 had atrial fibrillation, 13 had CABG, most were in functional class III-IV, 26 had conserved ejection fraction.
STS Score was 7.1%.
All procedures were femoral (37 with conscious sedation) and 2 were post-dilated.
Read also: EuroPCR 2022 | Galileo Trial: Mortality Predictors after Successful TAVR.
Technical success was seen in all patients. Neither of them crossed over to surgery, there were no deaths, major bleedings, or stroke, 9 required definite pacemaker (23%) and there were 3 minor bleedings.
Aortic valve area was 2.62 cm2 and mean gradient was 4 mmHg. There were no cases of moderate or severe AR and more than half did not present AR at all.
Dr. Carlos Fava.
Member of the Editorial Board of SOLACI.org.
Subscribe to our weekly newsletter
Get the latest scientific articles on interventional cardiology